Asia-Pacific Checkpoint Inhibitors market by Drug type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) by Application (Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others), & by Region - Industry Analysis, Share, Size, Growth, Trends, and Forecasts (2016-2021).

Asia-Pacific Checkpoint Inhibitors market by Drug type (PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others) by Application (Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others), & by Region - Industry Analysis, Share, Size, Growth, Trends, and Forecasts (2016-2021).

ID: 2180 | Pages: 143 | May 2017 | Region: Asia Pacific


Asia-Pacific Checkpoint Inhibitors Market has been estimated at USD 1.22 billion in 2016 and is projected to reach USD 4.48 billion by 2021, at a CAGR of 29.8% during the forecast period from 2016 to 2021.

Immune system uses checkpoints to avoid the overactivation of immune system on normal cells. Cancer cells uses these checkpoints to escape immune system by arraying with normal cells. Checkpoint inhibitors are drugs which blocks these normal cells and let immune system attack cancer cells. This is one of the treatment available in Immunotherapy.

Rising Prevalence of cancer globally, and increasing funding and government support towards developing new drugs are some of the factors driving the growth of the market. However, high expense involved in R&D activities is one of the major factors restricting the growth of the market.

Asia-Pacific Checkpoint Inhibitors Market is segmented based on Drug type and Application. Based on Drug type, market is segmented into PD-1 inhibitors, PD-L1 inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Others. Based on Application, market is segmented into Lung cancer, Renal cancer, Blood cancer, Bladder Cancer, Hodgkin lymphoma, Melanoma, Others. CTLA-4 Segment holds the highest share accounting for almost 94 % of the overall market. However, this segment is expected to lose some of its market to PD-1 inhibitors segment during the forecast period as majority of new treatments is based on PD-1 inhibitors.

Geographically, market is further segmented into India, China, Japan, Australia and South Korea. Asia-Pacific is the fastest growing region because of collaborations of international players with companies in this region.

Some of the key players in the Asia-Pacific checkpoint inhibitors market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

1.Introduction                                                                  

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                          

                1.4 General Study Assumptions                                                

2. Research Methodology                                                                           

                2.1 Introduction                                                               

                2.2 Research Phases                                                      

                                2.2.1 Secondary Research                                           

                                2.2.2 Primary Research                                 

                                2.2.3 Econometric Modelling                                      

                                2.2.4 Expert Validation                                  

                2.3 Analysis Design                                                         

                2.4 Study Timeline                                                          

3. Overview                                                                       

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 Epidemology                                                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                                                    

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                                              

5. Market Segmentation                                                                              

                5.1 Drug Type                                                   

                                5.1.1 Introduction                                           

                                5.1.2 PD-1 inhibitors                                       

                                5.1.3 PD-L1 inhibitors                                     

                                5.1.4 CTLA-4                                      

                                5.1.5  Chimeric Antigen Receptor T-cell                                 

                                5.1.6  Others                                     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type                                           

                                5.1.8 Market Attractiveness Analysis, By Drug Type                                         

                                5.1.9 Market Share Analysis, By Drug Type                                          

                5.2 Application                                                 

                                5.2.1 Introduction                                           

                                5.2.2 Lung cancer                                            

                                5.2.3 Renal cancer                                           

                                5.2.4 Blood cancer                                          

                                5.2.5 Bladder Cancer                                      

                                5.2.6  Hodgkin lymphoma                                            

                                5.2.7 Melanoma                                              

                                5.2.8  Others                                     

                                5.2.9 Y-o-Y Growth Analysis, By Application                                         

                                5.2.10  Market Attractiveness Analysis, By Application                                   

                                5.2.11  Market Share Analysis, By Application                                     

6. Geographical Analysis                                                                              

                6.1 Introduction                                                               

                                6.1.1 Regional Trends                                    

                                6.1.2 Impact Analysis                                     

                                6.1.3 Y-o-Y Growth Analysis                                        

                                                6.1.3.1 By Geographical Area                     

                                                6.1.3.2 By Drug Type                      

                                                6.1.3.3 By Application                    

                                6.1.4  Market Attractiveness Analysis                                     

                                                6.1.4.1 By Geographical Area                     

                                                6.1.4.2 By Drug Type                      

                                                6.1.4.3 By Application                    

                                6.1.5  Market Share Analysis                                      

                                                6.1.5.1 By Geographical Area                     

                                                6.1.5.2 By Drug Type                      

                                                6.1.5.3 By Application                    

                6.2 China                                                             

                6.3 India                                                              

                6.4 Japan                                                            

                6.5 South Korea                                                               

                6.6 Australia                                                      

7.Strategic Analysis                                                                        

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                       

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                                              

                                7.2.5 Competitive Rivalry within the Industry                                     

8.Market Leaders' Analysis                                                                         

                8.1 Merck & Co., Inc.                                                     

                                8.1.1 Overview                                 

                                8.1.2 Product Analysis                                   

                                8.1.3 Financial analysis                                  

                                8.1.4 Recent Developments                                       

                                8.1.5 SWOT analysis                                       

                                8.1.6 Analyst View                                          

                8.2 Bristol-Myers Squibb                                                              

                8.3 Roche                                                           

                8.4 AstraZeneca                                                               

                8.5 Ono Pharmaceutical Co., Ltd.                                                              

                8.6  Juno Therapeutics                                                  

                8.7 Novartis International AG                                                    

                8.8 Kite Pharma                                                               

9.Competitive Landscape                                                                            

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                       

                9.3 Agreements, collaborations and Joint Ventures                                                         

                9.4 New Product Launches                                                         

10.Market Outlook and Investment Opportunities                                                                          

Appendix                                                                           

                a) List of Tables                                                

                b) List of Figures                                                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
TitlePriceAdd To Cart
  1. Asia-Pacific Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  2. Asia-Pacific PD-1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  3. Asia-Pacific PD-L1 inhibitors Market By Region, From 2016-2021 ( USD Million )
  4. Asia-Pacific CTLA-4 Market By Region, From 2016-2021 ( USD Million )
  5. Asia-Pacific Chimeric Antigen Receptor T-cell Market By Region, From 2016-2021 ( USD Million )
  6. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  7. Asia-Pacific Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  8. Asia-Pacific Lung cancer Market By Region, From 2016-2021 ( USD Million )
  9. Asia-Pacific Renal cancer Market By Region, From 2016-2021 ( USD Million )
  10. Asia-Pacific Blood cancer Market By Region, From 2016-2021 ( USD Million )
  11. Asia-Pacific Bladder Cancer Market By Region, From 2016-2021 ( USD Million )
  12. Asia-Pacific Hodgkin lymphoma Market By Region, From 2016-2021 ( USD Million )
  13. Asia-Pacific Melanoma Market By Region, From 2016-2021 ( USD Million )
  14. Asia-Pacific Others Market By Region, From 2016-2021 ( USD Million )
  15. Japan Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  16. Japan Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  17. China Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  18. China Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  19. India Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  20. India Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  21. Australia Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  22. Australia Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
  23. South Korea Checkpoint Inhibitors Market By Drug Type, From 2016-2021 ( USD Million )
  24. South Korea Checkpoint Inhibitors Market By Application, From 2016-2021 ( USD Million )
Middle-East And Africa Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], ...
Latin America Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User ...
Asia-Pacific Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (...
Europe Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (Pharma...
North America Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User ...
Cell Counting Market By Product [(Instruments (Cell Counters, Hematology Analysers, Spectrophotometer, Flow Cytometer, Hemocytometer, Others), Consumables (Microplates, Reagent, Assay Kits)], End User (Pharmaceutica...
Middle East And Africa Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid T...
Latin America Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And...
Asia Pacific Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And ...
Europe Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And Others...
North America Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And...
Non-Invasive Cancer Diagnostics Market By Techniques (Clinical Chemistry, Immunochemistry, Molecular Diagnostics And Others), By Therapeutics (Blood Cancer, Breast Cancer, Lung Cancer, Solid Tumors And Others) And B...

"We Think Through Different Layers, We Work Across Different Verticals."

Market Data Forecast, Inc.
2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
+1-888-702-9626 (U.S. TOLL FREE)
contact@marketdataforecast.com


Subscribe To Our News Letter

Or follow us on social platform

© 2018 Market Data Forecast
All Rights Reserved.